格隆汇A股公告精选(9.13) | 药监局已受理恒瑞医药(600276.SH)新药上市申请;南方航空(600029.SH)8月客运运力投入升10.17%
以下为9月13日A股公告精选
【重大事项】
东湖高新(600133.SH)子公司中标2.17亿元第五资源热力电厂二期工程烟气净化系统采购及相关服务项目 亚泰集团(600881.SH)签订吉林省白求恩重离子肿瘤医院项目合作框架协议
恒瑞医药(600276.SH):国家药监局已受理卡瑞利珠单抗单药二线治疗晚期食管鳞癌、卡瑞利珠单抗联合培美曲塞加卡铂一线治疗晚期或转移性非鳞癌非小细胞肺癌的上市申请
华信新材(300717.SZ)拟将研发中心项目的建设周期延长
中闽能源(600163.SH):富锦市1×30MW农林生物质热电联产项目建设获核准
汇川技术(300124.SZ)及子公司7-8月累计获得政府补助5010.85万元
南京新百(600682.SH)拟收购蓝海科瑞100%的财产份额 将控股国内最大的专业脐带血库
龙元建设(600491.SH)中标7.28亿元内江市公共文化服务PPP项目
【增减持】
同济堂(600090.SH):盛世建金及其一致行动人盛世信金拟减持不超8637.98万股
科创新源(300731.SZ):苏州天利拟减持不超2%股份
先锋新材(300163.SZ):卢先锋及其一致行动人拟减持合计不超6.58%股份
富瀚微(300613.SZ):何辉拟减持不超2%股份
欣旺达(300207.SZ):北信瑞丰拟减持不超3065.45万股
【质押】
东方航空(600115.SH):均瑶集团质押3.12亿股A股 上海吉道航质押5.89亿股A股
欣旺达(300207.SZ):北信瑞丰拟减持不超3065.45万股
民生银行(600016.SH):中国泛海解押及质押8737万股
【财务数据】
春秋航空(601021.SH):8月客运量同比增长17.13% 环比增2.09%
中国化学(601117.SH)8月新签合同额达118.93亿元
南方航空(600029.SH)8月客运运力投入升10.17% 旅客周转量升10.35%
吉祥航空(603885.SH):8月客运量同比增12.67% 货运量增25.80%
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.